Planisware SAS (PLNW)
Euronext Paris · France · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 27.15 |
|---|---|
| 52-week range | 13.70 – 28.10 |
| Return, 1 month / 3 months | +11.3% / +39.1% |
| Return, 1 year / 3 years | +27.1% / – |
| Trend | Uptrend |
| RSI (14) | 63 |
| Volatility (1 year) | 40.2% |
| Worst drawdown (1 year) | -40.8% |
| Average daily value traded | 1.92M EUR |
| Dividend yield | 1.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Planisware is a French software company that develops enterprise project and portfolio management software. Its platform helps large organisations plan, manage and track projects, resources and product development activities. Customers include industrial, engineering, healthcare and public-sector organisations that need to coordinate complex programmes across teams. The company is based in France and provides its software to clients in several countries, along with related support and implementation services.
Planisware SAS trades under the code PLNW on the Euronext Paris in France, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Planisware SAS (PLNW) trades on the Euronext Paris in France. It last closed at EUR 27.15 on 23 October 2026.
Its price-based Market X-Ray is 71 out of 100 (a strong price profile), ranking 92 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 27.1% and over the last three months it rose 39.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 96 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 36.1% | ||
| From 52-week high | -2.9% | ||
| Momentum | 90 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 39.1% | ||
| 6-month return | 51.9% | ||
| 12-month return, skipping the last month | 14.2% | ||
| Stability (higher is calmer) | 45 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 40.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -40.8% | ||
| Liquidity | 83 · Strong | Trades actively. | |
| Average daily value traded | 1.92M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 8 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.3% | ||
| Years with dividends | 2 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.8% |
|---|---|
| 1 month | +11.3% |
| 3 months | +39.1% |
| 6 months | +51.9% |
| 1 year | +27.1% |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 24.74 / 19.94 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.99 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 Jun 2026 | EUR 0.3600 |
| 24 Jun 2025 | EUR 0.3100 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.